Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin- induced apoptosis in vitro and in vivo

Apoptosis

Volumn 16, Issue 5, 2011, Pages 511-523

  Gao, Ning ^a,b   Budhraja, Amit ^b   Cheng, Senping ^b   Liu, E Hu ^a   Huang, Cheng ^b   Chen, Jieping ^a   Yang, Zailin ^a   Chen, Deying ^a   Zhang, Zhuo ^b   Shi, Xianglin ^b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Apoptosis; Dihydroartemisinin; Leukemia; MEK ERK; Xenograft

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; DIHYDROARTEMISININ; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN MCL 1;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN U937; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARTEMISININS; CASPASES; CYTOCHROMES C; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HUMANS; LEUKEMIA; MAP KINASE KINASE KINASES; MICE; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; U937 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ARTEMISIA ANNUA;

EID: 79955820798     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-011-0580-6     Document Type: Article

References (50)

1. NJ White 2008 Qinghaosu (artemisinin): the price of success Science 320 330 334 18420924 10.1126/science.1155165 1:CAS:528:DC%2BD1cXks1Ghsbw%3D (Pubitemid 351555649)
2. PI German FT Aweeka 2008 Clinical pharmacology of artemisinin-based combination therapies Clin Pharmacokinet 47 91 102 18193915 10.2165/00003088- 200847020-00002
3. S Merali SR Meshnick 1991 Susceptibility of Pneumocystis carinii to artemisinin in vitro Antimicrob Agents Chemother 35 1225 1227 1929266 1:CAS:528:DyaK3MXksVGqt7k%3D
4. OY Ke EC Krug JJ Marr RL Berens 1990 Inhibition of growth of Toxoplasma gondii by qinghaosu and derivatives Antimicrob Agents Chemother 34 1961 1965 2291661 1:CAS:528:DyaK3MXitVyruw%3D%3D (Pubitemid 20290297)
5. T Efferth M Marschall X Wang SM Huong I Hauber A Olbrich, et al. 2002 Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses J Mol Med 80 233 242 11976732 10.1007/s00109-001-0300-8 1:CAS:528:DC%2BD38XksFGmsro%3D (Pubitemid 34439295)
6. MR Romero T Efferth MA Serrano B Castano RI Macias O Briz, et al. 2005 Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system Antiviral Res 68 75 83 16122816 10.1016/j.antiviral.2005.07.005 1:CAS:528:DC%2BD2MXhtFOhsb3J (Pubitemid 41565521)
7. SJ Kaptein T Efferth M Leis S Rechter S Auerochs M Kalmer, et al. 2006 The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo Antiviral Res 69 60 69 16325931 10.1016/j.antiviral.2005.10. 003 1:CAS:528:DC%2BD28XhtV2lsbw%3D (Pubitemid 43152041)
8. H Lai NP Singh 2006 Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene [DMBA]-induced breast cancer in the rat Cancer Lett 231 43 48 16356830 10.1016/j.canlet.2005.01.019 1:CAS:528: DC%2BD2MXhtlaitbfF (Pubitemid 41779452)
9. T Efferth H Dunstan A Sauerbrey H Miyachi CR Chitambar 2001 The anti-malaria artesunate is also active against cancer Int J Oncol 18 767 773 11251172 1:CAS:528:DC%2BD3MXivVWqtbw%3D
10. JM Wu F Shan GS Wu Y Li J Ding D Xiao, et al. 2001 Synthesis and cytotoxicity of artemisinin derivatives containing cyanoarylmethyl group Eur J Med Chem 36 469 479 11451535 10.1016/S0223-5234(01)01240-5 1:CAS:528: DC%2BD3MXltVahurg%3D (Pubitemid 32635218)
11. T Efferth A Ocbrich R Bauer 2002 mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether Biochem Pharmacol 64 617 623 12167480 10.1016/S0006-2952(02)01221-2 1:CAS:528:DC%2BD38XmtVWlsL4%3D
12. JC Moore H Lai JR Li RL Ren JA McDougall NP Singh, et al. 1995 Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat Cancer Lett 98 83 87 8529210 1:CAS:528: DyaK2MXpsV2nu70%3D
13. HJ Zhou JL Zhang A Li Z Wang XE Lou 2010 Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro Cancer Chemother Pharmacol 66 21 29 19756601 10.1007/s00280-009-1129-z 1:CAS:528:DC%2BC3cXkslalurw%3D
14. NP Singh HC Lai 2005 Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells Anticancer Res 25 4325 4331 16309236 1:CAS:528:DC%2BD2MXht12itL7M (Pubitemid 41665224)
15. NP Singh H Lai 2001 Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells Life Sci 70 49 56 11764006 10.1016/S0024-3205(01)01372-8 1:CAS:528:DC%2BD3MXovVSjtbg%3D (Pubitemid 33130042)
16. Q He J Shi XL Shen J An H Sun L Wang YJ Hu Q Sun LC Fu MS Sheikh Y Huang 2010 Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells Cancer Biol Ther 9 819 824 20224297 10.4161/cbt.9.10.11552 1:CAS:528:DC%2BC3cXhtlKrtrnF
17. T Chen M Li R Zhang H Wang 2009 Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy J Cell Mol Med 13 1358 1370 18466355 10.1111/j.1582-4934.2008.00360.x 1:CAS:528:DC%2BD1MXhtFCku7bE
18. XJ Huang ZQ Ma WP Zhang YB Lu EQ Wei 2007 Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells J Pharm Pharmacol 59 849 856 17637177 10.1211/jpp.59.6.0011 1:CAS:528:DC%2BD2sXmtlKntb0%3D (Pubitemid 47051097)
19. SJ Wang Y Gao H Chen R Kong HC Jiang SH Pan DB Xue XW Bai B Sun 2010 Dihydroartemisinin inactivates NF-κB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo Cancer Lett 293 99 108 20137856 10.1016/j.canlet.2010.01.001 1:CAS:528:DC%2BC3cXlsVyit70%3D
20. JJ Lu LH Meng YJ Cai Q Chen LJ Tong LP Lin 2008 Dihydroartemisinin induces apoptosis in HL60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species Cancer Biol Ther 7 1017 1023 18414062 10.4161/cbt.7.7.6035 1:CAS:528:DC%2BD1cXhtFWhs7vM
21. MR Sprick H Walczak 2004 The interplay between the Bcl-2 family and death receptor-mediated apoptosis Biochim Biophys Acta 1644 125 132 14996497 10.1016/j.bbamcr.2003.11.002 1:CAS:528:DC%2BD2cXhslWgu7Y%3D (Pubitemid 38281269)
22. AGS Buggins CJ Pepper 2010 The role of Bcl-2 family proteins in chronic lymphocytic leukaemia Leuk Res 34 837 842 20359747 10.1016/j.leukres.2010.03.011 1:CAS:528:DC%2BC3cXmsVSls7s%3D
23. S Derenne B Monia NM Dean JK Taylor MJ Rapp JL Harousseau, et al. 2002 Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells Blood 100 194 199 12070027 10.1182/blood.V100.1.194 1:CAS:528:DC%2BD38XltF2rsbo%3D (Pubitemid 35177447)
24. JH Cho-Vega GZ Rassidakis JH Admirand M Oyarzo P Ramalingam A Paraguya, et al. 2004 MCL-1 expression in B-cell non-Hodgkin's lymphomas Hum Pathol 35 1095 1100 15343511 10.1016/j.humpath.2004.04.018 1:CAS:528:DC%2BD2cXntFCjsb4%3D (Pubitemid 39165341)
25. W Sieghart D Losert S Strommer D Cejka K Schmid S Rasoul-Rockenschaub, et al. 2006 Mcl-1 overexpression in hepatocellular carcinoma: Apotential target for antisense therapy J Hepatol 44 151 157 16289418 10.1016/j.jhep.2005.09.010 1:CAS:528:DC%2BD2MXht12ktLvM (Pubitemid 41772529)
26. M Nguyen RC Marcellus A Roulston M Watson L Serfass SR Murthy Madiraju, et al. 2007 Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis Proc Natl Acad Sci USA 104 19512 19517 18040043 10.1073/pnas.0709443104 1:CAS:528:DC%2BD1cXisVOgsA%3D%3D
27. Y Andersson S Juell Q Fodstad 2004 Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin Int J Cancer 112 475 483 15382075 10.1002/ijc.20371 1:CAS:528:DC%2BD2cXovVels7k%3D (Pubitemid 39390614)
28. N Chetoui K Sylla JV Gagnon-Houde C Alcaide-Loridan D Charron R Al-Daccak, et al. 2008 Downregulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to Fas-mediated apoptosis Mol Cancer Res 6 42 52 18234961 10.1158/1541-7786.MCR-07-0080 1:CAS:528:DC%2BD1cXhtFyisbc%3D (Pubitemid 351378165)
29. Y Jiao CM Ge QH Meng JP Cao J Tong SJ Fan 2007 Dihydroartemisinin is an inhibitor of ovarian cancer cell growth Acta Pharmacol Sin 28 1045 1056 17588342 10.1111/j.1745-7254.2007.00612.x 1:CAS:528:DC%2BD2sXnvFynsLs%3D (Pubitemid 47020494)
30. L Chang M Karin 2001 Mammalian MAP kinase signalling cascades Nature 410 37 40 11242034 10.1038/35065000 1:CAS:528:DC%2BD3MXhvVSgs7k%3D (Pubitemid 32225829)
31. G Pearson F Robinson T Beers Gibson BE Xu M Karandikar K Berman, et al. 2001 Mitogen-activated protein [MAP] kinase pathways: regulation and physiological functions Endocr Rev 22 153 183 11294822 10.1210/er.22.2.153 1:CAS:528:DC%2BD3MXjsFSntL4%3D (Pubitemid 32458157)
32. Z Xia M Dickens J Raingeaud RJ Davis ME Greenberg 1995 Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis Science 270 1326 1331 7481820 10.1126/science.270.5240.1326 1:CAS:528:DyaK2MXpsFOhurc%3D
33. F Chang LS Steelman JT Lee JG Shelton PM Navolanic WL Blalock, et al. 2003 Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention Leukemia 17 1263 1293 12835716 10.1038/sj.leu.2402945 1:CAS:528:DC%2BD3sXkvFeqsro%3D (Pubitemid 36857335)
34. MR Ricciardi T McQueen D Chism M Milella E Estey E Kaldjian, et al. 2005 Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia Leukemia 19 1543 1549 16001087 10.1038/sj.leu.2403859 1:CAS:528:DC%2BD2MXovVOjur8%3D (Pubitemid 43090397)
35. CD Kang SD Yoo BW Hwang KW Kim DW Kim CM Kim SH Kim BS Chung 2000 The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells Leuk Res 24 527 534 10781688 10.1016/S0145-2126(00)00010-2 1:CAS:528:DC%2BD3cXislehurw%3D (Pubitemid 30227232)
36. WL Blalock M Pearce LS Steelman RA Franklin SA McCarthy H Cherwinski M McMahon JA McCubrey 2000 A conditionally active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells Oncogene 19 526 536 10698522 10.1038/sj.onc.1203337 1:CAS:528:DC%2BD3cXhsVyjur4%3D (Pubitemid 30099366)
37. WL Blalock PW Moye F Chang M Pearch S Steelman M McMahon JA McCubrey 2000 Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine-dependency of hematopoietic cells Adv Enzyme Regl 40 305 337 10.1016/S0065-2571(99)00033-3 (Pubitemid 30412540)
38. WL Blalock M Pearce F Chang JT Lee S Pohnert C Burrows LS Steelman RA Franklin M McMahon JA McCubrey 2001 Effects of inducible MEK1 activation on the cytokine-dependency of lymphoid cells Leukemia 15 794 807 11368441 10.1038/sj.leu.2402109 1:CAS:528:DC%2BD3MXks1Kks7c%3D (Pubitemid 32492703)
39. PE Hoyle PW Loye LS Steelman WL Blalock RA Franklin M Pearce H Cherwinski E Bosch M McMahon JA McCubrey 2000 Differential abilities of the Raf family of protein kinases to abrogate cytokine-dependency and prevent apoptosis in murine hematopoietic cells by a MEK-1 dependent mechanism Leukemia 14 642 656 10764150 10.1038/sj.leu.2401720 1:CAS:528:DC%2BD3cXivFOhurc%3D (Pubitemid 30195455)
40. M Milella SM Kornblau Z Estrov BZ Carter H Lapillonne D Harris, et al. 2001 Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia J Clin Invest 108 851 859 11560954 1:CAS:528: DC%2BD3MXmvV2ntb4%3D (Pubitemid 32880294)
41. A Bonni A Brunet AE West SR Datta MA Takasu ME Greenberg 1999 Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms Science 286 1358 1362 10558990 10.1126/science.286. 5443.1358 1:CAS:528:DyaK1MXnsVeku7s%3D (Pubitemid 29535895)
42. MP Scheid KM Schubert V Duronio 1999 Regulation of bad phosphorylation and association with Bcl-x[L] by the MAPK/Erk kinase J Biol Chem 274 31108 31113 10521512 10.1074/jbc.274.43.31108 1:CAS:528:DyaK1MXntVSls7w%3D (Pubitemid 29503956)
43. LA Allan N Morrice S Brady G Magee S Pathak PR Clarke 2003 Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK Nat Cell Biol 5 647 654 12792650 10.1038/ncb1005 1:CAS:528:DC%2BD3sXkvFeru7Y%3D (Pubitemid 36818087)
44. CM Leu C Chang C Hu 2000 Epidermal growth factor [EGF] suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway Oncogene 19 1665 1675 10763823 10.1038/sj.onc.1203452 1:CAS:528:DC%2BD3cXivVartLs%3D (Pubitemid 30200968)
45. C Nishioka T Ikezoe J Yang A Yokoyama 2010 Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1 Apoptosis 15 795 804 20221697 10.1007/s10495-010-0483-y 1:CAS:528:DC%2BC3cXotVOltb8%3D
46. P Lunghi N Giuliani L Mazzera G Lombardi M Ricca A Corradi AM Cantoni L Salvatore R Riccioni A Costanzo U Testa M Levrero V Rizzoli A Bonati 2008 Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways Blood 112 2450 2462 18583568 10.1182/blood-2007-10-114348 1:CAS:528:DC%2BD1cXhtFCru7%2FP
47. P Zhou L Qian KM Kozopas RW Craig 1997 Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions Blood 89 630 643 9002967 1:CAS:528:DyaK2sXlt1GrsQ%3D%3D (Pubitemid 27051700)
48. J Michels JW O'Neill CL Dallman A Mouzakiti F Habens M Brimmell, et al. 2004 Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage Oncogene 23 4818 4827 15122313 10.1038/sj.onc.1207648 1:CAS:528:DC%2BD2cXkvVOis7w%3D (Pubitemid 38932154)
49. L Liu Y Cao C Chen X Zhang A McNabola D Wilkie S Wilhelm M Lynch C Carter 2006 Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 11851 11858 17178882 10.1158/0008-5472.CAN-06-1377 1:CAS:528: DC%2BD28Xhtlagu73F (Pubitemid 46094197)
50. J Hou D Wang R Zhang H Wang 2008 Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action Clin Cancer Res 14 5519 5530 18765544 10.1158/1078-0432.CCR-08-0197 1:CAS:528:DC%2BD1cXhtVKmsbnE